RE: Avacta and revolutionary tech12 Nov 2020 09:06
I am happy for the balanced discussion, but I think everyone needs to think about the PR aspect here... Pfizer Albert Bourla sells 62% on announcement of vaccine. Vaccine hasn't been peer reviewed (absolute shocker says GSK person) and then dumps and runs? Why? Vaccine has HUGE logistical issues and sets marketing in a free spin with massive spikes in leisure and testing stocks in free fall. As soon as new less problematic vaccine is available (maybe oxford?) then Pfizer will be forgotten. Never mind Albert is ok... Now a vaccination programme will take at least a year to roll out here (very few dispute that) and globally several years. Due to compressed development timescales, we are effectively guinea pigs for any vaccine. This will have an impact on take up and from what is clear from the Pfizer data is that it won't be effective for everyone. Those will covid symptoms will still want/need to know what they have... so it can be checked and monitored and the government will need to keep a track of the spread for at least 2-4 years... albeit at a reduced requirement probably. I can't see how testing can be stopped if we don't know how long even a vaccine might be good for? Or even in the case of mutations. The market as I see is there, and Avacta certainly have a chance at it... but we won't know until the figures are in. That is where we are now and we will be subjected to sentiment until that is cleared up.